Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Radioiodine-refractory Differentiated Thyroid Cancer”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Very early researchLooking for participantsNCT06898437
What this trial is testing

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Large-scale testing (Phase 3)Ended earlyNCT03602495
What this trial is testing

Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Testing effectiveness (Phase 2)Study completedNCT01813136
What this trial is testing

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Centre Leon Berard 168
Testing effectiveness (Phase 2)Looking for participantsNCT06359847
What this trial is testing

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited 60
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Post-approval studies (Phase 4)Study completedNCT03573960
What this trial is testing

Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Who this might be right for
Thyroid Neoplasms
Eisai Pharmaceuticals India Pvt. Ltd 50
Not applicableStudy completedNCT01534897
What this trial is testing

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Who this might be right for
Papillary Thyroid Carcinoma
Massachusetts General Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT06959641
What this trial is testing

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more
Northwestern University 33
Not applicableApproved For MarketingNCT02211222
What this trial is testing

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Eisai Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04061980
What this trial is testing

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Who this might be right for
BRAF NP_004324.2:p.V600MBRAF V600E Mutation PresentMetastatic Thyroid Gland Carcinoma+4 more
Providence Health & Services 24
Not applicableLooking for participantsNCT07068542
What this trial is testing

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Who this might be right for
Advanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid CancerPoorly Differentiated Thyroid Carcinoma
Zhejiang Provincial People's Hospital 94
Testing effectiveness (Phase 2)UnknownNCT03167385
What this trial is testing

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid Carcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Not applicableLooking for participantsNCT05994365
What this trial is testing

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 380
Large-scale testing (Phase 3)Study completedNCT01876784
What this trial is testing

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Genzyme, a Sanofi Company 238
Large-scale testing (Phase 3)Study completedNCT02966093
What this trial is testing

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Eisai Co., Ltd. 151
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Large-scale testing (Phase 3)Active Not RecruitingNCT03690388
What this trial is testing

Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Who this might be right for
Differentiated Thyroid Cancer
Exelixis 187
Load More Results